Ajanta Pharma jumped 4.56% to Rs 1507.95 after consolidated net profit jumped 45.3% to Rs 129.16 crore on 32.4% surge in net sales to Rs 681.96 crore in Q4 March 2020 over Q4 March 2019.
Profit before tax (PBT) rose 61.06% to Rs 175.86 crore in Q4 March 2020 over Q4 March 2019. Current tax expense jumped 272.97% to Rs 49.53 crore during the quarter. Consolidated EBITDA grew at 19% to Rs 151 crore in Q4 March 2020 over Q4 March 2019.During the quarter, India sales were up 11% to Rs 177 crore in Q4 March 2020 as compared to Rs 159 crore in Q4 March 2019. As per IQVIA MAT March 2020, the company posted a healthy growth of 11% in Cardiology (segment growth of 11%), 17% in Ophthalmology (segment growth of 11%), 6% in Dermatology (segment growth of 9%) and 16% in Pain Management (segment growth of 12%).
Total exports soared 43% to Rs 490 crore in Q4 March 2020 from Rs 343 crore in Q4 March 2019. The pharma company's emerging market branded generic sale surged 38% year-on-year basis to Rs 304 crore in Q4 March 2020. US generic sale stood at 143 crore, recording a sensational growth of 88% on year on year basis in Q4 March 2020.
The company said R&D expenses were at Rs 50 crore in Q4 March 2020, (Q4 FY 2019 Rs 40 crore) which is 7% of operating revenue.
Ajanta Pharma's consolidated net profit surged 21% to Rs 467.70 crore on 25.9% rise in net sales to Rs 2587.87 crore in the year ended March 2020 (FY20) over the year ended March 2019 (FY19). PBT rose 29.11% to 663.97 crore in FY20 over FY19.
Ajanta Pharma is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app